GUF1

Across TCGA pan-cancer cohorts, GUF1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GUF1 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher GUF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GUF1 expression acts as an unfavorable survival marker.

LIHC, MESO, and COAD are the cancer types where GUF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	III,IV	0.051	0.650	<.001	27	view →
MESO	OS	Median	All	0.130	0.557	.019	18	view →
COAD	OS	Median	III,IV	0.163	0.791	.004	12	view →
LGG	DFS	Median	All	0.228	0.739	<.001	6	view →
SKCM	OS	Median	III,IV	0.259	0.708	.007	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GUF1–LIHC (OS)

Open the LIHC breakdown →